ARCHIVES

House Committee Alleges Irregularities In Tamoxifen Trial Informed Consent Forms

This article is from The Cancer Letter archive.

Vol. 18 No. 42 | October 30, 1992

Download PDF Visit The Full Archive

Related Articles

Amgen Halts Phase III Trial Of Ganitumab Plus Gemcitabine

August 31, 2012

Part II of Q&A With NCI Director Harold Varmus

July 29, 2011

NCI-Approved Clinical Trials For The Month of June

June 24, 2011

No Interest Seen Yet In Specialized Centers For Environmental Carcinogenesis

September 26, 1975

ACS President & COO Resigns Unexpectedly; Was Seen as Contender for CEO Position

December 19, 2014

CMS Looks At Coverage of Two Agents Approved on Surrogate Endpoints

March 21, 2003